Clinical Trials
Tourette Syndrome Phase IIb
TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with comorbidities. Currently used medications manage only a small number of disease symptoms, with limited efficacy and questionable safety.
Efficacy signal
21%
reduction in tic severity
The Phase IIb trial received FDA approval to proceed following a successful open-label Phase IIa trial led by Yale University, which showed an approximately 21% reduction in tic severity.
Study design
SCI-110
Investigational drug
Multicenter, randomized, double-blind, placebo-controlled study evaluating safety, efficacy and tolerability of daily oral SCI-110 in adults aged 18–65 with TS.
Trial sites
03
Trial sites
Yale Child Study Center, Yale School of Medicine, Connecticut, USA
Medizinische Hochschule Hannover, Hannover, Germany
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel